

Furoscix[®] (furosemide) – Expanded indication

- On March 7, 2025, [scPharmaceuticals announced](#) the FDA approval of [Furoscix \(furosemide\)](#), for the **treatment of edema in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.**
 - Furoscix was previously approved for the treatment of congestion due to fluid overload in adults with chronic heart failure. **This approval expands the use of Furoscix to include patients with CKD.**
- The single-use, On-body Infusor with prefilled cartridge is pre-programmed to deliver 30 mg of Furoscix subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.
 - Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.
 - Furoscix is intended for use in a setting where the patient can limit their activity for the duration of administration.